Skip to content

The Clinical Study on the Impact of Digital Mobile Medical Technology on Diabetes Prevention and Management

The Clinical Study on the Impact of Digital Mobile Medical Technology on Diabetes Prevention and Management

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080050
Enrollment
Unknown
Registered
2024-01-18
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Diabetes precision self-management AI model group:Patients are required to install APP on their smartphones. Patients learn knowledge about diabetes through the short video pushed by the APP, includin
Control group:Traditional health education for diabetes

Sponsors

Affiliated Jiangning Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diabetes patients aged 18–70 years, treated for their diabetes by the recruiting health care provider, sufficiently fluent in Chinese, wtih the ability to use smartphones and proficient in using smartphone applications.The patient has the ability of daily blood glucose measurement, and the patient can sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) with presence of cognitive impairment or psychiatric disorders; (2) when diagnosed with type 1 diabetes mellitus, gestational diabetes mellitus or special types of diabetes mellitus. (3) with severe heart, liver or kidney failure, malignant tumors or other serious diseases; (4) when refused to sign the informed consent; (5) with pregnancy during the planned study; (6) with a history of alcoholism and drug abuse; (7) when using drugs that may affect blood glucose levels, such as glucocorticoids and thyroid hormones; (8) with cardiovascular and cerebrovascular events occurred within 6 months before enrollment; (9) with severe hearing or visual impairment; (10) when unable to access the network or learn to use smart phones; (11) or if patients are simultaneously participating in another clinical trial.

Design outcomes

Primary

MeasureTime frame
Hemoglobin A1c;

Secondary

MeasureTime frame
Weight;Fasting blood glucose;2-Hour postprandial blood glucose ;Triglyceride;Cholesterol;Low density lipoprotein cholesterol;High density lipoprotein cholesterol;Creatinine;Urea;Uric acid;Urinary microalbumin / creatinine;Presence of microvascular complications ;Presence of macrovascular complications;The Short Form (36) Health Survey;The Audit of Diabetes-Dependent Quality of Life (ADDQoL);Diabetes Treatment Satisfaction Questionnaire (DTSQ);Summary of Diabetes Self-Care Activities Measure (SDSCA);Body mass index;Blood pressure;Waist circumference;Hip perimeter;Insulin;C-peptide;Homeostasis model assessment of insulin resistance ( HOMA-IR);Homeostasis model assessment of ß cell function (HOMA-ß;The perceived quality of APP;The frequency of application usage;the cost-effectiveness ;Glutamic-pyruvic transaminase ;Glutamic oxaloacetic transaminase ;EuroQol 5 Dimensions 5 Level instrument (EQ-5D-5L);

Countries

China

Contacts

Public ContactSu wang

Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing Jiangning Hospital

313965655@qq.com+86 151 9047 9967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026